261 related articles for article (PubMed ID: 28038443)
1. HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis.
Zhou X; Li Q; He J; Zhong L; Shu F; Xing R; Lv D; Lei B; Wan B; Yang Y; Wu H; Mao X; Zou Y
Oncotarget; 2017 Mar; 8(12):19342-19353. PubMed ID: 28038443
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of hnRNP A2/B1 inhibits cell proliferation, invasion and cell cycle triggering apoptosis in cervical cancer via PI3K/AKT signaling pathway.
Shi X; Ran L; Liu Y; Zhong SH; Zhou PP; Liao MX; Fang W
Oncol Rep; 2018 Mar; 39(3):939-950. PubMed ID: 29328485
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
4. HnRNP-L mediates bladder cancer progression by inhibiting apoptotic signaling and enhancing MAPK signaling pathways.
Lv D; Wu H; Xing R; Shu F; Lei B; Lei C; Zhou X; Wan B; Yang Y; Zhong L; Mao X; Zou Y
Oncotarget; 2017 Feb; 8(8):13586-13599. PubMed ID: 28088793
[TBL] [Abstract][Full Text] [Related]
5. HnRNP L is important for the expression of oncogene SRSF3 and oncogenic potential of oral squamous cell carcinoma cells.
Jia R; Zhang S; Liu M; Zhang Y; Liu Y; Fan M; Guo J
Sci Rep; 2016 Nov; 6():35976. PubMed ID: 27808105
[TBL] [Abstract][Full Text] [Related]
6. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.
Zhang Y; Yuan Y; Liang P; Zhang Z; Guo X; Xia L; Zhao Y; Shu XS; Sun S; Ying Y; Cheng Y
Oncotarget; 2017 Jul; 8(28):45459-45469. PubMed ID: 28525372
[TBL] [Abstract][Full Text] [Related]
8. Fyn/heterogeneous nuclear ribonucleoprotein E1 signaling regulates pancreatic cancer metastasis by affecting the alternative splicing of integrin β1.
Jiang P; Li Z; Tian F; Li X; Yang J
Int J Oncol; 2017 Jul; 51(1):169-183. PubMed ID: 28560430
[TBL] [Abstract][Full Text] [Related]
9. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.
Gang X; Yang Y; Zhong J; Jiang K; Pan Y; Karnes RJ; Zhang J; Xu W; Wang G; Huang H
Oncotarget; 2016 Mar; 7(12):15135-49. PubMed ID: 26934656
[TBL] [Abstract][Full Text] [Related]
10. SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer.
Yuan D; Wang W; Su J; Zhang Y; Luan B; Rao H; Cheng T; Zhang W; Xiao S; Zhang M; Jiang FN; Sun Z; Jia Z; Zhong WD; Zhu J
Curr Cancer Drug Targets; 2018; 18(9):894-904. PubMed ID: 29295692
[TBL] [Abstract][Full Text] [Related]
11. Activation of BDNF/TrkB pathway promotes prostate cancer progression via induction of epithelial-mesenchymal transition and anoikis resistance.
Li T; Yu Y; Song Y; Li X; Lan D; Zhang P; Xiao Y; Xing Y
FASEB J; 2020 Jul; 34(7):9087-9101. PubMed ID: 32390303
[TBL] [Abstract][Full Text] [Related]
12. EBF1-Mediated Upregulation of Ribosome Assembly Factor PNO1 Contributes to Cancer Progression by Negatively Regulating the p53 Signaling Pathway.
Shen A; Chen Y; Liu L; Huang Y; Chen H; Qi F; Lin J; Shen Z; Wu X; Wu M; Li Q; Qiu L; Yu N; Sferra TJ; Peng J
Cancer Res; 2019 May; 79(9):2257-2270. PubMed ID: 30862720
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
[TBL] [Abstract][Full Text] [Related]
14. SMC1A promotes growth and migration of prostate cancer in vitro and in vivo.
Pan XW; Gan SS; Ye JQ; Fan YH; Hong Υ; Chu CM; Gao Y; Li L; Liu X; Chen L; Huang Y; Xu H; Ren JZ; Yin L; Qu FJ; Huang H; Cui XG; Xu DF
Int J Oncol; 2016 Nov; 49(5):1963-1972. PubMed ID: 27667360
[TBL] [Abstract][Full Text] [Related]
15. TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.
Navone NM; Rodriquez-Vargas MC; Benedict WF; Troncoso P; McDonnell TJ; Zhou JH; Luthra R; Logothetis CJ
Clin Cancer Res; 2000 Mar; 6(3):1190-7. PubMed ID: 10741751
[TBL] [Abstract][Full Text] [Related]
16. ING5 inhibits cancer aggressiveness via preventing EMT and is a potential prognostic biomarker for lung cancer.
Zhang F; Zhang X; Meng J; Zhao Y; Liu X; Liu Y; Wang Y; Li Y; Sun Y; Wang Z; Mei Q; Zhang T
Oncotarget; 2015 Jun; 6(18):16239-52. PubMed ID: 25938545
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer via caspase-1 activation.
Chang I; Mitsui Y; Kim SK; Sun JS; Jeon HS; Kang JY; Kang NJ; Fukuhara S; Gill A; Shahryari V; Tabatabai ZL; Greene KL; Dahiya R; Shin DM; Tanaka Y
Oncotarget; 2017 Jun; 8(24):39087-39100. PubMed ID: 28388569
[TBL] [Abstract][Full Text] [Related]
18. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.
Zhou L; Song Z; Hu J; Liu L; Hou Y; Zhang X; Yang X; Chen K
Theranostics; 2021; 11(2):841-860. PubMed ID: 33391508
[TBL] [Abstract][Full Text] [Related]
19. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA‑198 suppresses prostate tumorigenesis by targeting MIB1.
Ray J; Hoey C; Huang X; Jeon J; Taeb S; Downes MR; Boutros PC; Liu SK
Oncol Rep; 2019 Sep; 42(3):1047-1056. PubMed ID: 31322262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
